VR Adviser’s Relmada Therapeutics RLMD Stock Holding History

VR Adviser’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.4M	Buy	6,844,305 +2,000,925	+41%	+$14M	1.44%	15
2026 Q1	$33.7M	Buy	+4,843,380	New	+$22.9M	1.26%	21
2022 Q4	–	Sell	-1,518,056	Closed	-$56.2M	–	33
2022 Q3	$56.2M	Sell	1,518,056 -752,016	-33%	-$20.8M	8.67%	4
2022 Q2	$43.1M	Hold	2,270,072	–	–	8.49%	3
2022 Q1	$61.3M	Hold	2,270,072	–	–	9.93%	3
2021 Q4	$51.1M	Buy	2,270,072 +882,352	+64%	+$19.6M	6.99%	4
2021 Q3	$36.4M	Hold	1,387,720	–	–	4.67%	9
2021 Q2	$44.4M	Buy	1,387,720 +534,514	+63%	+$18.6M	5.39%	6
2021 Q1	$30M	Buy	853,206 +184,766	+28%	+$6.46M	3.26%	12
2020 Q4	$21.4M	Hold	668,440	–	–	3.15%	10
2020 Q3	$25.1M	Hold	668,440	–	–	4.92%	7
2020 Q2	$29.9M	Sell	668,440 -174,374	-21%	-$7.37M	7.16%	4
2020 Q1	$28.7M	Buy	+842,814	New	+$34M	7.79%	3

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VR Adviser's RLMD Position: Q2 2026 in Review

VR Adviser increased its Relmada Therapeutics (RLMD) stake by 41% in Q2 2026, buying an estimated $14M and bringing the position to 6,844,305 shares worth $47.4M. The position accounts for 1.44% of the portfolio, ranked #15.

VR Adviser first reported a position in RLMD in Q1 2020 and has held it in 13 quarters since. The position peaked at $61.3M in Q1 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

VR Adviser held 6,844,305 shares of Relmada Therapeutics worth $47.4M as of Q2 2026.
VR Adviser bought 2,000,925 Relmada Therapeutics shares in Q2 2026, an estimated $14M.
Relmada Therapeutics made up 1.44% of VR Adviser's portfolio in Q2 2026, its #15 holding.
VR Adviser first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 13 quarters since.
VR Adviser's Relmada Therapeutics position peaked at $61.3M in Q1 2022.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.